Saudi Arabia vs Tunisia: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Saudi Arabia
- Tunisia
How they compare
Saudi Arabia currently reports 247.11 deaths against 198.78 deaths in Tunisia, a difference of 48.33 deaths.
That makes Saudi Arabia's figure about 1.2 times Tunisia's.
The two have swapped places 3 times across 35 shared years of data; in 1990 it was Tunisia ahead.
Saudi Arabia ranks 107th and Tunisia ranks 110th of 157 countries.
Saudi Arabia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Saudi Arabia | Tunisia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 56.24 deaths | 0 deaths | 56.24 deaths | Saudi Arabia |
| 2000s | 210.83 deaths | 23.7 deaths | 187.13 deaths | Saudi Arabia |
| 2010s | 142.31 deaths | 81.37 deaths | 60.94 deaths | Saudi Arabia |
| 2020s | 221.23 deaths | 164.95 deaths | 56.28 deaths | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Saudi Arabia or Tunisia?
- Saudi Arabia, at 247.11 deaths against 198.78 deaths in Tunisia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Saudi Arabia and Tunisia?
- 48.33 deaths, with Saudi Arabia ahead.
- How many years of comparable data are there for Saudi Arabia and Tunisia?
- 35 years are reported by both, from 1990 to 2024.
- How do Saudi Arabia and Tunisia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Saudi Arabia ranks 107th and Tunisia ranks 110th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.